{"id":"dexamethasona-idarubicine-ara-c-methotrexate","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiotoxicity (idarubicine-related)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Neurotoxicity (methotrexate-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone is a corticosteroid that reduces inflammation and promotes apoptosis in leukemic cells. Idarubicine intercalates DNA and inhibits topoisomerase II, causing DNA damage. ARA-C (cytarabine) is incorporated into DNA as a false nucleotide, disrupting replication. Methotrexate inhibits dihydrofolate reductase, blocking nucleotide synthesis. Together, these agents target acute leukemia cells through complementary cytotoxic pathways.","oneSentence":"This is a combination chemotherapy regimen that uses a corticosteroid, an anthracycline topoisomerase II inhibitor, a nucleoside antimetabolite, and a folate antagonist to kill rapidly dividing leukemic cells through multiple mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:44:28.602Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"}]},"trialDetails":[{"nctId":"NCT01366898","phase":"PHASE4","title":"Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2007-06-30","conditions":"Acute Lymphoblastic Leukemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dexamethasona, Idarubicine, ARA-C, Methotrexate","genericName":"Dexamethasona, Idarubicine, ARA-C, Methotrexate","companyName":"PETHEMA Foundation","companyId":"pethema-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination chemotherapy regimen that uses a corticosteroid, an anthracycline topoisomerase II inhibitor, a nucleoside antimetabolite, and a folate antagonist to kill rapidly dividing leukemic cells through multiple mechanisms. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}